Affiliation:
1. State Key Laboratory of Quality Research in Chinese Medicines and Macau Institute for Applied Research in Medicine and Health Macau University of Science and Technology Macau China
Abstract
AbstractThe increased transmissibility of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Delta and Omicron variants due to their complex mutations has been confirmed by many studies, but the disease severity caused by these two variants and vaccine efficacy have not been clearly concluded. This meta‐analysis evaluated and compared disease severity and vaccine efficacy for infection with these two variants. Databases were searched on July 29, 2022, for original studies. Data extracted included participants, hospitalization rate, intensive care unit (ICU) admission rate, mortality rate, and vaccination status. Total 15 studies (570,713 subjects) were included. The risk of hospitalization, ICU admission and death in patients with Delta were increased compared with patients with Omicron, especially hospitalization (Log risk ratio [RR]: 1.09, 95% confidence interval [CI]: 0.65–1.53). The Delta was associated with a higher risk of death in the unvaccinated population (Log RR: 0.48, 95% CI: 0.04–0.93). No significant differences in the risk of severe illness between BA.1 and BA.2 were observed. All three risks were reduced in fully vaccinated populations infected with Delta and Omicron. The existing evidence shows that the inherent virulence and disease severity of Omicron are reduced compared with Delta, and fully vaccination is effective in preventing severe infection of both variants.
Reference43 articles.
1. SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India
2. In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion
3. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
4. WHO. Classification of Omicron (B.1.1.529): SARS‐CoV‐2 Variant of Concern. Accessed August 5 2022.https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern
5. WHO. Naming SARS‐CoV‐2 Variants. Accessed August 14 2022.https://www.who.int/activities/tracking-SARS-CoV-2-variants
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献